inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: A clinicopathologic, cytogenetic, and molecular study of five cases

Mihai Merzianu, L. Jeffrey Medeiros, Jorge Cortes, Cameron Yin, Pei Lin, Dan Jones, Armand Glassman, Hagop Kantarjian, Yang Huh

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Blast phase (BP) in chronic myelogenous leukemia (CML) frequently is accompanied by cytogenetic abnormalities in addition to t(9;22)(q34;q11.2). We describe 5 patients with CML in blast phase (CML-BP) in which t(9;22) and inv(16)(p13q22) were identified by conventional cytogenetics, with confirmation of BCR/ABL and CBFβ/MYH11 by fluorescence in situ hybridization. The morphologic findings at the time of BP resembled de novo acute myeloid leukemia (AML) carrying inv(16)(p13q22), with abnormal eosinophils in the bone marrow and monocytosis in the peripheral blood in all cases. In 1 patient, inv(16)(p13q22) and abnormal eosinophils were detected in the bone marrow 2 months before CML-BP. The clinical course of these patients was similar to patients with CML-BP without evidence of inv(16)(p13q22). These cases illustrate that inv(16)(p13q22) is a form of cytogenetic evolution that rarely occurs in patients with CML at the time of BP. In this setting, unlike de novo AML, inv(16)(p13q22) in CML-BP is not associated with a favorable prognosis.

Original languageEnglish (US)
Pages (from-to)807-814
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume124
Issue number5
DOIs
StatePublished - Nov 2005
Externally publishedYes

Keywords

  • Blast phase
  • Chronic myelogenous leukemia
  • Clonal evolution
  • inv(16)
  • t(9;22)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: A clinicopathologic, cytogenetic, and molecular study of five cases'. Together they form a unique fingerprint.

  • Cite this